Navigation Links
Cephalon, Inc. to Present at the J.P. Morgan Healthcare Conference
Date:1/8/2009

FRAZER, Pa., Jan. 8 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that Frank Baldino, Jr., Ph.D., Chairman and CEO will present at the J.P. Morgan Healthcare Conference, to be held on January 13, 2009 in San Francisco, CA at approximately 4:00 p.m. Pacific Time (7 p.m. Eastern Time). The presentation will be webcast live on the investor relations section of the company's website.

The webcast will be archived for one week following the broadcast. To access the webcast, log on to the company's website at www.cephalon.com and click on "Investors," then "Webcast." Click on the link and follow the prompts for registration and access.

About Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of many unique products in three core therapeutic areas: central nervous system, pain, and oncology. A member of the Fortune 1000 and the S&P 500 Index, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. The company's European headquarters are located in Maisons-Alfort, France.

The company's proprietary products in the United States include: AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules), TREANDA(R) (bendamustine hydrochloride) for Injection, FENTORA(R) (fentanyl buccal tablet) [C-II], PROVIGIL(R) (modafinil) Tablets [C-IV], TRISENOX(R) (arsenic trioxide) injection, GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(R) (armodafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1-800-896-5855.

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products; interpretation of clinical results; prospects for regulatory approval; manufacturing development and capabilities; market prospects for its products; sales, adjusted net income and basic adjusted income per common share guidance; and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.


'/>"/>
SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Biopharmaceutical Company, Cephalon, To Pay $425 Million & Enter Plea to Resolve Allegations of Off-Label Marketing
2. Wyeth to Present at the JP Morgan Healthcare Conference
3. VNUS Medical Technologies to Present at 27th Annual J.P. Morgan Healthcare Conference
4. Celator(R) Pharmaceuticals To Present at Biotech Showcase 2009
5. Warner Chilcott to Present at the 27th Annual JP Morgan Healthcare Conference
6. Pharmasset to Present at the 27th Annual JPMorgan Healthcare Conference
7. Isis Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
8. Digirad Corporation CEO to Present at J.P. Morgan Healthcare Conference in San Francisco
9. Insulet Corporation to Present at the J.P. Morgan Healthcare Conference on January 14, 2009
10. Stryker To Present at Investor Conference
11. Immunomedics to Present at 27th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... CA (PRWEB) , ... May 24, 2017 , ... ... today its participation in nVerge 2017 – a one-day technology conference in San Diego, ... document management solution, which allows users to fully utilize and enhance their Sage ERP ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. Manju R. Kejriwal, a leading Ohio ... with or without a referral. Dr. Kejriwal understands the emotional and financial toll traditional ... in Cincinnati, OH. Patients no longer need to feel the esthetic effects of wires ...
(Date:5/24/2017)... ... 24, 2017 , ... Myers Jackson is well known for auctioning homes that ... homes anywhere on the planet. The luxury home market is alive and well and ... A quick search of “11 Spyglass Hill Auction will enlighten you on the dynamics ...
(Date:5/24/2017)... ... , ... Medic CE , a Career Step company, is sponsoring a ... by the Journal of Emergency Medical Services (JEMS). The free webinar, to be held ... Captain Rommie Duckworth, LP, a career fire captain as well as founder and director ...
(Date:5/24/2017)... ... May 24, 2017 , ... Adelberg-Montalvan Pediatric Dentistry ... for its patients on Long Island, New York. , Holistic dentistry puts ... is one of the biggest trends in dentistry today. , Dentist Dr. ...
Breaking Medicine News(10 mins):
(Date:5/6/2017)... SKANEATELES FALLS, N.Y. , May 5, 2017 /PRNewswire/ ... expansion that will add approximately 100,000 square feet to ... announced in September 2016 its commitment to bring more ... York , where Welch Allyn has maintained a ... facility will help accommodate these new positions, a large ...
(Date:5/4/2017)... SAN DIEGO , May 4, 2017 /PRNewswire/ ... is demonstrating its wireless, handheld ultrasound scanners this ... Gynecologists Annual Scientific Meeting (ACOG) in ... 2017. "Clarius is the perfect ... fetal growth and heart rate, and evaluate pregnancy-related ...
(Date:5/4/2017)...  A new tight-tolerance microextrusion medical tubing product ... is being launched by Natvar, a Tekni-Plex company. ... recent years to service a wide variety of ... expensive materials such as glass and fluoropolymers have ... their ability to consistently hold tolerances. This is ...
Breaking Medicine Technology: